The clinical, laboratory, and standard echocardiographic data of the patients with sarcoidosis and the control group
| Parameters | Patients with sarcoidosis N=28 | Control group N=24 | p value |
|---|---|---|---|
| Age, years | 40.22±11.92 | 37.57±5.20 | 0.640 |
| Gender, F/M | 15/13 | 13/11 | 0.435 |
| BMI, kg/m2 | 25.29±2.4 | 24.75±2.0 | 0.35 |
| Smokers (n) | 28 | 30 | 0.6 |
| SBP, mm Hg | 118.40±8.02 | 119.28±10.15 | 0.963 |
| DBP, mm Hg | 71.62±8.05 | 74.04±8.89 | 0.329 |
| HR, bpm | 81.92±8.23 | 77.09±5.62 | 0.124 |
| Total cholesterol (mg/dL) | 176.6±27.3 | 159.4±31.8 | 0.119 |
| Fasting glucose (mg/dL) | 90.4±9.9 | 86.1±11.8 | 0.098 |
| CRP (mg/L) | 1.7±0.4 | 0.4±0.1 | <0.001 |
| LVEF, % | 64.14±2.55 | 65.80±2.40 | 0.260 |
| Mitral E wave (cm/s) | 78.6±16.0 | 90.0±12.8 | 0.01 |
| Mitral A wave(cm/s) | 72.2±20.1 | 62.3±9.0 | 0.04 |
| Mitral DT (ms) | 186.9±34.8 | 193.0±28.6 | 0.2 |
| Mitral E/A ratio | 1.07+0.32 | 1.2+0.36 | 0.03 |
| RVEDA, cm2 | 25.25±9.20 | 20.57±7.33 | 0.032 |
| RVESA, cm2 | 14.07±4.48 | 14.61±4.29 | 0.673 |
| RVFAC, % | 44.96±6.19 | 51.47±5.34 | <0.001 |
| TAPSE, cm | 1.92±0.24 | 2.43±0.40 | <0.001 |
| PASP, mm Hg | 32.54±5.84 | 24.36±3.78 | 0.003 |
A p value <0.05 was accepted as statistically significant.
BMI, body mass index; CRP, C reactive protein; DBP, diastolic blood pressure; DT, deceleration time; F, female; HR, heart rate; LVEF, left ventricular ejection fraction; M, male; PASP, pulmonary arterial systolic pressure; RVEDA, right ventricular end-diastolic area; RVESA, right ventricular end-systolic area; RVFAC, right ventricular fractional area change; SBP, systolic blood pressure; TAPSE, tricuspid annular plane systolic excursion.